Mankind Pharma Limited — Q2FY27 earnings call summary

Filed 30 October 2026 · Official transcript

Consumer healthcare growth muted; single-digit growth expected in FY27; recovery anticipated in FY28
Q2 FY27 revenue grew 17% y-y to Rs 4,338 Cr; EBITDA up 27.2% to Rs 1,175 Cr; margin improved 210 bps to 27.1%
Gross margin expanded 90 bps to 72.2%; R&D spend at 2.5% of sales, below 3% guidance
Net debt reduced to Rs 2,639 Cr; net debt/EBITDA at 0.6x; capex at 4.9% of revenue
Management confident of sustaining IPM outperformance; chronic share target 50% in 4-5 years
ACTx funding secured till FY28; open to partnerships or further investment based on clinical results
Domestic business ex-consumer grew 15.9% y-y; chronic share rose 80 bps to 37.4%
International business grew 33% y-y; BSV specialty and new US launches driving growth